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ABSTRACT 1 
AIMS To ascertain the relationship between level of physical activity and outcomes and to 2 
discriminate the determinants of physical activity performance or avoidance. 3 
METHODS CLARIFY is an international prospective registry of 32370 consecutive outpatients 4 
with stable coronary artery disease who were followed for up to 5 years. Patients were grouped 5 
according to the level and frequency of physical activity: i) sedentary (n=5223; 16.1%); ii) only 6 
light physical activity most weeks (light; n=16634; 51.4%); iii) vigorous physical activity once or 7 
twice per week (vigorous ≤2×; n=5427; 16.8%); iv) vigorous physical activity three or more times 8 
per week (vigorous >2×; n=5086; 15.7%). The primary outcome was the composite of 9 
cardiovascular death, myocardial infarction, and stroke. 10 
RESULTS Patients performing vigorous physical activity ≤2× had the lowest risk of the primary 11 
outcome (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.71-0.93; P = .0031) taking the 12 
light group as reference. Engaging in more frequent exercise did not result in further outcome 13 
benefit. All-cause death, cardiovascular death, and stroke occurred less frequently in patients 14 
performing vigorous physical activity ≤2×. However, the rate of myocardial infarction was 15 
comparable between the four physical activity groups. Female sex, peripheral artery disease, 16 
diabetes, previous myocardial infarction or stroke, pulmonary disease, and body mass index all 17 
emerged as independent predictors of lower physical activity. 18 
CONCLUSION Vigorous physical activity once or twice per week was associated with superior 19 
cardiac outcomes compared to patients performing no or a low level of physical activity in 20 
outpatients with stable coronary artery disease.  21 
KEYWORDS stable coronary artery disease; physical activity. 22 
  23 
4 
Introduction 1 
International guidelines suggest 30-60 minutes of moderate-to-vigorous intensity aerobic exercise 2 
on most, preferably all, days of the week for patients with stable coronary artery disease (SCAD).1 3 
This recommendation is derived from a single meta-analysis with >80% of the included studies 4 
dating back to the last century.2 Recent observations have now challenged this dogma. A post-hoc 5 
analysis from the randomized Stabilization of Atherosclerotic Plaque by Initiation of Darapladib 6 
Therapy (STABILITY) study3 showed that increased habitual exercise levels were associated with 7 
lower all-cause mortality and: i) the benefit was more pronounced at lower versus higher exercise 8 
levels; and ii) myocardial infarction (MI) and stroke are not reduced by exercise and are not related 9 
to its intensity or frequency. Another post-hoc analysis from the Nord-Trøndelag Health (HUNT) 10 
study showed that sustained strenuous physical activity is associated with a prognostic benefit in 11 
patients with SCAD during a long time span (30 years).4 12 
Thus, it is not clear which exercise frequency and intensity are linked to the best outcome. 13 
This information is relevant for SCAD patients as they are likely to undertake less exercise due to 14 
symptoms such as angina or dyspnea and to the psychological consequences of the disease. 15 
Moreover, several other questions remain unanswered, including how to encourage SCAD patients 16 
to exercise.5-7 Guidelines suggest that clinicians should explore practical ways to overcome barriers 17 
to exercise.1 However, clinical and socio-economic determinants of levels of physical activity are 18 
unclear and interventions aimed at increasing physical activity levels are based on common sense or 19 
physicians’ personal experience. 20 
CLARIFY is a large international, prospective contemporary dataset describing features and 21 
long-term outcomes of patients with SCAD. The present analysis of the CLARIFY population was 22 
performed with the following aims: i) to ascertain the relationship between level of physical activity 23 
(assessed by self-response to a question at baseline) and outcomes and ii) to describe the 24 
determinants of physical activity performance or avoidance. 25 
 26 
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Methods 1 
Study Design and Population 2 
CLARIFY is a prospective, international, contemporary, observational, longitudinal registry of 3 
consecutive outpatients with SCAD who are receiving standard management. The rationale, design, 4 
and baseline characteristics of CLARIFY have previously been reported.8, 9 Patients were enrolled 5 
in 45 countries in Africa, Asia, Australia, Europe, the Middle East, and North, Central, and South 6 
America, according to prespecified criteria and were followed for up to 5 years, in order to reach an 7 
epidemiologically representative population in each country.8 Study participation did not alter usual 8 
clinical practice. CLARIFY enrolled patients with at least one of the following non-mutually 9 
exclusive criteria: documented MI >3 months before enrolment; angiographic demonstration of 10 
coronary stenosis >50%; chest pain with evidence of myocardial ischemia (stress 11 
electrocardiogram); or coronary artery bypass graft (CABG) or percutaneous coronary intervention 12 
(PCI) >3 months before enrolment. Enrollment started on November 26, 2009 and recruitment was 13 
completed on June 30, 2010. The study is in accordance with the principles in the Declaration of 14 
Helsinki and local ethical approval was obtained in all countries prior to recruitment. All patients 15 
gave written informed consent and the study is registered (ISRCTN43070564).  16 
 17 
Data Collection 18 
Electronic case report forms were completed at baseline and annually during the follow-up. Data 19 
quality was pursued via onsite monitoring visits, regular telephone contact with investigators, and 20 
centralized verification of the case report forms. At baseline and follow-up, data were collected on 21 
demographics, risk factors and lifestyle, medical history, physical condition and activity, vital signs, 22 
current symptoms, and current treatments. Available results of invasive and non-invasive tests were 23 
collected, although no test was mandated by the study. Clinical outcomes were recorded on a yearly 24 
basis.  25 
 26 
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Physical Activity Assessment 1 
Physical activity was self-reported by the patients at the inclusion visit. A scale categorized the 2 
population into four groups according to the level and frequency of physical activity: i) no physical 3 
activity (sedentary); ii) only light physical activity during most weeks (light); iii) vigorous physical 4 
activity for ≥20 minutes once or twice a week (vigorous ≤2×); and iv) vigorous physical activity for 5 
≥20 minutes three or more times per week (vigorous >2×). Vigorous activity was defined as causing 6 
shortness of breath, a rapid heart rate, and sweating. During follow-up, no further evaluation of 7 
physical activity was performed.  8 
 9 
Outcomes 10 
The primary outcome of the present analysis is the composite of cardiovascular death, MI, or stroke. 11 
Secondary outcomes are all-cause death and each component of the primary outcome. Patients were 12 
followed for up to 5 years. For composite outcomes, patients with more than one event were only 13 
counted once at first event. Events were not adjudicated, but all events were source-verified during 14 
audits, which were performed for 100% of the data at 5% of randomly selected sites.  15 
 16 
Statistical Analysis 17 
Baseline characteristics are presented using descriptive statistics with mean (standard deviation 18 
[SD]) or median (quartiles 1 and 3) for continuous variables, and number of observed values (%) 19 
for categorical variables. Baseline values were compared between the four physical activity level 20 
groups using analysis of variance (ANOVA) or Kruskal-Wallis tests for continuous variables, 21 
depending on the distribution of the data, and χ2 tests for categorical variables. Univariate Cox 22 
proportional-hazards models were used to provide hazard ratios (HRs) and corresponding 95% 23 
confidence intervals (CIs) to evaluate the relationship between each of the baseline variables and 24 
the primary outcome. Variables that were significant at the 10% level (probability value <0.1) from 25 
the univariate analyses were allowed to enter into a stepwise model. The stepwise model then 26 
7 
entered or removed variables from this reduced list based on a significance level of 5% (probability 1 
value <0.05).  A final multivariable model was then obtained for the primary outcome using the 2 
statistically significant independent predictors from the resultant stepwise model. Models for each 3 
of the secondary outcomes were also obtained using these statistically significant independent 4 
predictors. Determinants of physical activity as a binary variable (vigorous activity [≤2× or >2×] 5 
compared to sedentary or light) were identified via multivariable logistic regression analyses, 6 
generating odds ratios (ORs) and corresponding 95% CIs for the effect of each baseline variable on 7 
the outcome of interest. Statistical analysis was performed at the Robertson Centre for Biostatistics 8 
at the University of Glasgow, UK using the statistical program SAS (version 9.3). 9 
 10 
Results 11 
For the present analysis, the study population comprised 32 370 subjects with available information 12 
regarding level of physical activity at baseline (98.0% of those enrolled) (eFigure 1). The largest 13 
group was the light physical activity group (n = 16 634, 51.4%), while the other three groups had a 14 
comparable number of patients (sedentary: n = 5223 [16.1%]; vigorous ≤2×: n = 5427 [16.8%]; 15 
vigorous >2×: n = 5086 [15.7%]). As expected, baseline demographics, risk factors, lifestyle, 16 
medical history, vital signs, symptoms, measurements, and medications were different in the four 17 
groups (Table 1 and eTables 1 and 2). In particular, sedentary patients and those undertaking only 18 
light physical activity were older; had higher body mass indexes (BMIs); higher prevalence of 19 
diabetes, peripheral artery disease (PAD), and current smoking, had worse symptoms as indicated 20 
by New York Heart Association (NYHA) classes; and had lower mean left ventricular ejection 21 
fractions (LVEFs) compared to those who undertook vigorous physical activity (≤2× or >2× each 22 
week) (Table 1). 23 
 24 
Kaplan-Meier Plots of Primary and Secondary Outcomes 25 
The primary outcome (cardiovascular death, MI, or stroke) occurred in 2807 patients (8.6%). A 26 
8 
Kaplan-Meier plot of time to first event of the composite primary outcome shows that this was most 1 
likely to occur among sedentary patients, followed by those undertaking only light activity, then 2 
those undertaking vigorous activity >2× (Figure 1). Kaplan-Meier plots for all-cause death, MI, 3 
cardiovascular death, and stroke showed similar trends, although this was least pronounced for MI 4 
(eFigures 2-5). 5 
 6 
Univariate Analysis 7 
Univariate analysis identified multiple risk factors, most notably estimated glomerular filtration rate 8 
(eGFR) <30 mL/min/1.73 m2 (HR, 4.12; 95% CI, 3.28-5.17, eGFR 60-89.99 mL/min/1.73m2 as 9 
reference), hospitalization for congestive heart failure (CHF) (HR, 2.95; 95% CI, 2.62-3.31), age 10 
≥75 years (HR, 2.73; 95% CI, 2.48-2.99, age <65 years as reference), and combined CHF and 11 
NYHA class III (HR, 2.55; 95% CI, 2.16-3.01, no CHF as reference) (eTable 3). Patients 12 
performing vigorous physical activity ≤2× or >2× experienced a lower risk of the primary outcome 13 
than patients performing light physical activity (≤2×: HR, 0.70; 95% CI, 0.62-0.79; >2×: HR, 0.71; 14 
95% CI, 0.62-0.80), while sedentary patients had a higher risk of the primary outcome (HR, 1.58; 15 
95% CI, 1.44-1.73). 16 
 17 
Multivariable Analysis 18 
Physical activity remained a predictor of the primary outcome after multivariable stepwise 19 
regression (Table 2, Figure 2). Patients performing vigorous physical activity ≤2× had the best 20 
outcome (HR, 0.82; 95% CI, 0.71-0.93). Engaging in more frequent exercise was not associated 21 
with further benefit, with no difference between the outcomes of the vigorous >2× group versus the 22 
light activity group (HR, 0.94; 95% CI, 0.82-1.07). Sedentary patients had the highest risk of the 23 
primary outcome (HR, 1.31; 95% CI, 1.18-1.46; Table 2, Figure 2).  24 
 25 
Secondary Outcomes 26 
9 
All secondary outcomes were evaluated in a model adjusting for multivariable analysis predictors 1 
(Figure 2). Patients who performed vigorous physical activity ≤2× had a lower risk of some of the 2 
secondary outcomes compared to the light physical activity group (all-cause death: HR, 0.81; 95% 3 
CI, 0.70-0.94; cardiovascular death: HR, 0.79; 95% CI, 0.65-0.96; stroke: HR, 0.74; 95% CI, 0.56-4 
0.98). However, the risk of MI was comparable between the four groups (Figure 2). 5 
 6 
Logistic Regression Analysis of Physical Activity Determinants 7 
Logistic regression analysis identified multiple correlates of physical activity (eTable 4), of which 8 
the most significant determinants are presented in Figure 3. Correlates of lower physical activity 9 
included race/ethnicity (Chinese, Latin American), not working full time, smoking, and various 10 
comorbidities (e.g. CHF, angina, PAD, diabetes, chronic obstructive pulmonary disease 11 
[COPD]/asthma). Correlates of higher physical activity included race/ethnicity (Japanese/Korean), 12 
male, higher education, moderate alcohol consumption, family history of coronary artery disease, 13 
and dyslipidemia.  14 
 15 
Discussion 16 
There are five main observations derived from the present study. Firstly, in SCAD patients, 17 
performing some exercise is associated with a beneficial outcome in terms of all-cause mortality, 18 
cardiovascular mortality, myocardial infarction, and stroke. Secondly, by different levels of 19 
exercise, vigorous physical activity once or twice a week is associated with lower cardiovascular 20 
and all-cause mortality at 5 years. Thirdly, the risk of MI is not associated with exercise, 21 
irrespective of levels. Fourthly, Chinese race/ethnicity, female sex, less education, not working full 22 
time, CHF, COPD/asthma, diabetes, and smoking appear among the main determinants for avoiding 23 
physical activity. Lastly, the relationship between level of activity and outcome is not linear, i.e. 24 
although vigorous activity ≤2× is associated with superior outcomes to light activity, and light 25 
activity is associated with superior outcomes to sedentary, a higher frequency of vigorous physical 26 
10 
activity was not associated with greater clinical benefit. 1 
The present study, with its global geographic scope, confirms a non-linear relationship 2 
between the frequency and intensity of physical activity and a lower risk of adverse clinical 3 
outcomes. However, the relationship between optimal intensity and frequency of physical activity 4 
and outcomes in patients with SCAD is complex and controversial. Also, the risk of an adverse 5 
clinical outcome is greater in SCAD patients who are also more likely to have exercise-limiting 6 
symptoms. 7 
Among heart attack survivors, strenuous physical activity (running >50 km per week) has 8 
been associated with an excess risk of cardiovascular mortality not related to the traditional 9 
cardiovascular risk factors.10 In fact, strenuous exercise in SCAD patients elicits instant and general 10 
inflammation, as well as procoagulant activity and platelet and endothelial activation,11, 12 thus 11 
increasing cardiovascular risks such as MI13 or sudden death.14 On the other hand, in the 12 
STABILITY trial, SCAD patients who performed physical activity volumes below current 13 
recommendations also had a lower mortality risk than sedentary patients.3, 15  14 
A reverse J-shaped association of physical activity with prognosis among patients with 15 
SCAD has also been observed in terms of physical activity frequency. In the KAROLA study, both 16 
inactive and daily active patients had increased hazards of mortality compared to the reference 17 
group of patients who were active 2-4 times per week.16 A similar finding has been observed in a 18 
recent meta-analysis on the effect of physical activity in a general population of older people (≥60 19 
years, n = 22 709).17 Meta-regressions on mortality showed that exercise 2-3 times per week 20 
appeared to be the optimal frequency of exercise.17 21 
Studies that have investigated physical activity changes over time have shown that the 22 
difference in mortality is greater when increasing activity at lower levels of habitual exercise, and 23 
less pronounced when increasing activity at higher levels of exercise,3 supporting the concept that 24 
the association between physical activity level and outcome in SCAD patients is not linear.15 25 
Our data show that vigorous physical activity with moderate frequency (once or twice per 26 
11 
week) was associated with the lowest risk of all-cause and cardiovascular death, while those who 1 
undertake vigorous physical activity more frequently had a mortality rate comparable to those with 2 
light activity. Thus, the goal with SCAD patients should be to promote sustainable physical activity 3 
and reduce the number of sedentary patients, rather than achieving the highest possible frequency of 4 
vigorous physical activity. Another important finding is that even achieving a lower level of 5 
physical activity (only light physical activity most weeks) is related to a prognostic benefit when 6 
compared to no physical activity. Thus, the message for SCAD patients and healthcare 7 
professionals should be that it is paramount to perform even light physical activity rather than be 8 
sedentary, and that non-strenuous physical activity (≥20 minutes of vigorous physical activity once 9 
or twice per week) is associated with the best outcome. This goal is theoretically achievable for 10 
most SCAD patients, but was only reached in a third of the CLARIFY population. Patients should 11 
also be advised that a higher frequency of physical activity does not appear to be related to greater 12 
benefit.  13 
The mechanism for cardiovascular and non-cardiovascular mortality reduction secondary to 14 
physical activity is still unclear. In the STABILITY study,3 reduction of cardiovascular death was 15 
independent from prevention of MI or stroke. Our analysis failed to show a reduction in MI, but 16 
stroke was reduced. This is the first documentation of physical activity-related stroke reduction in a 17 
large SCAD population. Previous studies in the general population have reported an association 18 
between increased physical activity and reduced occurrence of either ischemic or hemorrhagic 19 
stroke, in both men and women.18-23  20 
In our study, approximately half of the patients were in the light physical activity group. 21 
This is not surprising, as SCAD patients are likely to be cautious about exercising or limited by 22 
their symptoms. However, most SCAD patients who report low physical activity are not 23 
significantly limited by symptoms and, when symptoms are limiting, they are generally non-specific 24 
symptoms such as shortness of breath, fatigue, and weakness.24 Equally, SCAD patients who 25 
participate in rehabilitation programs are generally not symptom-limited, and are usually younger 26 
12 
men with less comorbidities.25  1 
After adjustment for confounders in the STABILITY population, older age, male sex, and 2 
obesity were associated with lower physical activity.26 We performed a broader characterization of 3 
the physical activity determinants. Ethnicity significantly impacted on the level of physical activity, 4 
with Japanese/South Korean or South Asian origin being associated with higher levels of physical 5 
activity, Chinese or Latin American origin with lower. This could be related to the higher income in 6 
some countries than in other countries, leading to more awareness that a sedentary lifestyle is a risk 7 
factor for CAD. In line with this, lack of full-time employment, and lower level of education are 8 
also correlated with lower levels of exercise. 9 
In contrast with the STABILITY study,26 our analysis shows that being female is strongly 10 
associated with a lower level of physical activity, indicating that women are less frequently enrolled 11 
in cardiac rehabilitation programs and have less intensive lifestyle counseling.25 12 
Comorbidities (e.g. PAD, diabetes) and the severity of cardiovascular disease (i.e. 13 
congestive heart failure, Canadian Cardiovascular Society and NYHA class, and previous MI or 14 
stroke), smoking, and higher BMI were also associated with a lower level of exercise. Thus, 15 
patients “at risk” for not exercising (i.e. women and complex patients with comorbidities) can be 16 
readily identified and should be targeted for further intervention, counseling, or rehabilitation in 17 
order to achieve at least a light physical activity level. In fact, in the STABILITY population, more 18 
complex patients had a greater benefit from a physically active lifestyle.15 19 
 20 
Limitations 21 
There are some limitations to be acknowledged. First, physical activity levels were collected by 22 
questionnaires, which can overestimate activity and have poor agreement with objective 23 
measurement of physical activity.27 In particular, the definition of vigorous was subjective and 24 
information regarding volume of endurance and strength training is lacking. In addition, physical 25 
activity level was self-reported at baseline. Thus, we did not capture the impact of changes in the 26 
13 
level of activity during the 5-year follow-up. Further, we could not ascertain whether the level of 1 
physical activity was sustained during follow-up, and studies have suggested that sustained physical 2 
activity confers the largest cardiovascular prognostic benefits in patients with CAD.4, 10 We did not 3 
collect information regarding participation to rehabilitation program that could have been 4 
prognostically impactful. Lastly, although we corrected for baseline characteristics in the 5 
multivariable analysis, there may have been unmeasured confounders, and differences in prognosis 6 
according to level of physical activity could be related to reverse causality, being patients with 7 
lowest physical activity older patients, with a high risk profile and less ideally medically treated. 8 
 9 
Conclusions 10 
Vigorous physical activity performed once or twice per week was associated with substantially 11 
lower cardiovascular and all-cause mortality compared to patients performing no or a low level of 12 
physical activity. However, more frequent vigorous activity was not associated with superior 13 
outcomes. 14 
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Figure 1. Kaplan-Meier Plot of Time to First Primary Endpoint, by Physical Activity Level 1 
 2 
  3 
19 
Figure 2. Primary and Secondary Endpoint Hazard Ratios According to Physical Activity 1 
Level after Multivariable Stepwise Regression Analysis 2 
 3 
Abbreviations: CI, confidence interval; CV, cardiovascular; HR, hazard ratio; MI, myocardial 4 
infarction. 5 
 6 
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Figure 3. Most Significant Determinants of Physical Activity as a Binary Variable (Vigorous 1 
Activity [≤2× or >2×] Compared to Sedentary or Light) after Multivariable Logistic 2 
Regression Analysis 3 
  4 
 5 
Abbreviations: BMI, body mass index; CAD, coronary artery disease; CCS, Canadian 6 
Cardiovascular Society; CHF, congestive heart failure; COPD, chronic obstructive pulmonary 7 
disease; MI, myocardial infarction; NYHA, New York Heart Association; PAD: peripheral artery 8 
disease.9 
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Table 1. Baseline Clinical and Socio-Economic Features by Weekly Physical Activity 
Information All (n = 32 
370) 
Sedentary 
(n = 5223) 
Light (n = 16 
634) 
Vigorous 
≤2× (n = 
5427) 
Vigorous 
>2× (n = 
5086) 
P 
Value 
Male, No. (%) 25 107 (77.6) 3540 (67.8) 12 620 (75.9) 4562 (84.1) 4385 (86.2) <.0001 
Age, mean (SD), 
years 
64.2 (10.5) 66.5 (10.9) 64.5 (10.4) 62.5 (10.2) 62.5 (10.1) <.0001 
Race/ethnicity, No. (%) <.0001 
  Caucasian 20 945 (64.7) 3054 (58.5) 10 962 (65.9) 3702 (68.2) 3227 (63.4)  
  South Asian 2415 (7.5) 355 (6.8) 1217 (7.3) 356 (6.6) 487 (9.6)  
  Chinese 2740 (8.5) 362 (6.9) 1972 (11.9) 197 (3.6) 209 (4.1)  
  Japanese/Korean 1035 (3.2) 237 (4.5) 345 (2.1) 205 (3.8) 248 (4.9)  
  Latin American 1568 (4.8) 475 (9.1) 668 (4.0) 191 (3.5) 234 (4.6)  
  Black/African 337 (1.0) 67 (1.3) 155 (0.9) 60 (1.1) 55 (1.1)  
  Unknown 3330 (10.3) 673 (12.9) 1315 (7.9) 716 (13.2) 626 (12.3)  
Employment, No. (%) <.0001 
  Full-time 7894 (24.4) 857 (16.4) 3543 (21.3) 1795 (33.1) 1699 (33.4)  
  Part-time 2249 (6.9) 256 (4.9) 1203 (7.2) 444 (8.2) 346 (6.8)  
  Unable to work 1265 (3.9) 257 (4.9) 716 (4.3) 145 (2.7) 147 (2.9)  
  Unemployed 1831 (5.7) 586 (11.2) 838 (5.0) 222 (4.1) 185 (3.6)  
  Retired 17 916 (55.4) 2949 (56.5) 9723 (58.5) 2695 (49.7) 2549 (50.1)  
  Other 1213 (3.7) 318 (6.1) 609 (3.7) 126 (2.3) 160 (3.1)  
Level of education, No. (%) <.0001 
  ≤Primary 8571 (26.5) 2191 (41.9) 4173 (25.1) 1155 (21.3) 1052 (20.7)  
 22 
  Secondary 15 033 (46.4) 2099 (40.2) 7986 (48.0) 2571 (47.4) 2377 (46.7)  
  College/ 
university 
8764 (27.1) 933 (17.9) 4473 (26.9) 1701 (31.3) 1657 (32.6)  
Family history of 
CAD, No. (%) 
9214 (28.5) 1288 (24.7) 4518 (27.2) 1733 (31.9) 1675 (32.9) <.0001 
Treated 
hypertension, No. 
(%) 
22 987 (71.0) 4010 (76.8) 12 105 (72.8) 3638 (67.0) 3234 (63.6) <.0001 
Diabetes, No. (%) 9390 (29.0) 2033 (38.9) 4937 (29.7) 1247 (23.0) 1173 (23.1) <.0001 
Dyslipidemia, No. 
(%) 
24 253 (74.9) 3711 (71.1) 12 396 (74.5) 4188 (77.2) 3958 (77.8) <.0001 
PAD, No. (%) 3203 (9.9) 660 (12.6) 1732 (10.4) 440 (8.1) 371 (7.3) <.0001 
Smoking status, No. (%) <.0001 
  Current 4039 (12.5) 784 (15.0) 2119 (12.7) 661 (12.2) 475 (9.3)  
  Former 14 967 (46.2) 2004 (38.4) 7511 (45.2) 2675 (49.3) 2777 (54.6)  
  Never 13 364 (41.3) 2435 (46.6) 7004 (42.1) 2091 (38.5) 1834 (36.1)  
MI, No. (%) 19 398 (59.9) 3008 (57.6) 10 195 (61.3) 3216 (59.3) 2979 (58.6) <.0001 
PCI, No. (%) 18 954 (58.6) 3057 (58.5) 9401 (56.5) 3297 (60.8) 3199 (62.9) <.0001 
CABG, No. (%) 7628 (23.6) 1201 (23.0) 3837 (23.1) 1306 (24.1) 1284 (25.2) .0076 
Stroke 1301 (4.0) 306 (5.9) 711 (4.3) 165 (3.0) 119 (2.3) <.0001 
TIA, No. (%) 993 (3.1) 210 (4.0) 510 (3.1) 153 (2.8) 120 (2.4) <.0001 
Hospitalization for 
CHF, No. (%) 
1512 (4.7) 365 (7.0) 842 (5.1) 173 (3.2) 132 (2.6) <.0001 
 23 
Asthma/COPD, 
No. (%) 
2393 (7.4) 536 (10.3) 1288 (7.7) 324 (6.0) 245 (4.8) <.0001 
BMI, mean (SD), 
kg/m2 
27.9 (4.6) 28.6 (5.3) 27.9 (4.7) 27.6 (4.0) 27.3 (3.9) <.0001 
SBP, mean (SD), 
mmHg 
131.1 (16.7) 131.6 
(17.2) 
131.6 (16.9) 130.5 
(16.1) 
129.4 
(16.0) 
<.0001 
DBP, mean (SD), 
mmHg 
77.3 (10.0) 76.8 (10.2) 77.5 (10.1) 77.6 (9.6) 76.7 (9.8) <.0001 
Heart rate by ECG, 
mean (SD), bpm 
67.1 (11.4) 68.9 (12.1) 67.8 (11.4) 66.0 (11.0) 64.6 (10.8) <.0001 
CCS Class, No. (%) <.0001 
  Class I 2051 (28.6) 227 (21.7) 1132 (26.3) 377 (33.8) 315 (44.6)  
  Class II 3812 (53.2) 577 (55.2) 2345 (54.5) 578 (51.9) 312 (44.2)  
  Class III 1225 (17.1) 221 (21.1) 779 (18.1) 155 (13.9) 70 (9.9)  
  Class IV 78 (1.1) 21 (2.0) 44 (1.0) 4 (0.4) 9 (1.3)  
NYHA Class, No. (%) <.0001 
  Class II 4098 (83.6) 541 (74.2) 2589 (84.0) 650 (88.3) 318 (90.1)  
  Class III 803 (16.4) 188 (25.8) 494 (16.0) 86 (11.7) 35 (9.9)  
LVEF, mean (SD), 
% 
56.1 (11.1) 54.4 (11.9) 55.8 (11.1) 56.9 (10.3) 57.9 (10.6) <.0001 
Abbreviations: BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery 
disease; CCS, Canadian Cardiovascular Society; CHF, congestive heart failure; COPD, chronic 
obstructive pulmonary disease; DBP, diastolic blood pressure; ECG, electrocardiogram; LVEF, left 
ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; 
PAD, peripheral artery disease; PCI, percutaneous coronary intervention; SBP, systolic blood 
pressure; SD, standard deviation; TIA, transient ischemic attack.  
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Table 2. Multivariable Analysis of Predictors of the Composite Primary Endpoint 
 25 
 HR (95% CI) Overall and 
(Individual) 
P Valuesa 
Physical activity (vs light)  <.001 
  Sedentary 1.31 (1.18-1.46) (<.001) 
  Vigorous ≤2× 0.82 (0.71-0.93) (.003) 
  Vigorous >2× 0.94 (0.82-1.07) (.324) 
Race/Ethnicity (vs Caucasian)  <.001 
  South Asian 1.01 (0.84-1.20) (.947) 
  Chinese 0.87 (0.73-1.02) (.086) 
  Japanese/Korean 0.67 (0.48-0.94) (.018) 
  Latin American 1.19 (0.98-1.44) (.075) 
  Black/African 1.75 (1.23-2.47) (.002) 
  Unknown 0.95 (0.79-1.14) (.595) 
Employment (vs full-time)  <.001 
  Part-time 1.16 (0.94-1.44) (.177) 
  Unable to work 1.46 (1.16-1.83) (.001) 
  Unemployed 1.232 (0.99-1.53) (.062) 
  Retired 1.36 (1.18-1.57) (<.001) 
  Other 1.12 (0.86-1.46) (.412) 
Diabetes (vs no) 1.25 (1.15-1.37) <.001 
PAD (vs no) 1.27 (1.13-1.43) <.001 
Smoking status (vs never)  <.001 
  Current 1.59 (1.38-1.82) (<.001) 
  Former 1.29 (1.17-1.42) (<.001) 
 26 
Hospitalization for CHF (vs no) 1.49 (1.29-1.74) <.001 
Asthma/COPD (vs no) 1.17 (1.02-1.34) .023 
MI (vs no) 1.28 (1.17-1.40) <.001 
Stroke (vs no) 1.72 (1.47-2.00) <.001 
DBP (per 10 mmHg) 0.95 (0.90-0.99) .032 
Hemoglobin (vs 8-8.99 mmol/L)  <.001 
  <8 mmol/L 1.22 (1.08-1.38) (.002) 
  9-9.99 mmol/L 0.98 (0.86-1.11) (.736) 
  >10 mmol/L 1.29 (1.05-1.59) (.017) 
  Missing 0.95 (0.83-1.08) (.406) 
SBP (per 10 mmHg) 1.045 (1.014-1.076) .004 
Age (vs <65 years)  <.001 
  65-74 years 1.33 (1.18-1.49) (<.001) 
  ≥75 years 2.06 (1.81-2.36) (<.001) 
Combined angina and CCS class (vs no angina)  .003 
  Class I 1.26 (1.07-1.49) (.005) 
  Class II 1.06 (0.92-1.21) (.437) 
  Class III/IV 1.34 (1.09-1.65) (.006) 
Aspirin (vs no) 0.76 (0.68-0.85) <.001 
Combined CHF and NYHA class (vs no CHF)  .003 
  Class II 1.24 (1.09-1.41) (<.001) 
  Class III 1.19 (0.94-1.50) (.146) 
eGFR group vs 60-89.99 mL/min/1.73 m2   <.001 
  <30 mL/min/1.73 m2  1.92 (1.46-2.53) (<.001) 
  30-44.99 mL/min/1.73 m2  1.49 (1.25-1.77) (<.001) 
 27 
  45-59.99 mL/min/1.73 m2  1.21 (1.06-1.37) (.006) 
  ≥90 mL/min/1.73 m2  1.00 (0.87-1.15) (.994) 
  Missing 1.14 (0.99-1.31) (.077) 
Heart rate (per 2 bpm) 1.03 (1.01-1.05) .004 
LVEF (vs 40-50%)  <.001 
  <40% 1.29 (1.10-1.51) (.002) 
  >50% 0.72 (0.64-0.81) (<.001 
  Missing 0.89 (0.78-1.01) (.064) 
Vessel disease (vs 0)  <.001 
  1  1.01 (0.79-1.29) (.919) 
  ≥2 1.30 (1.03-1.65) (.030) 
Abbreviations: CCS, Canadian Cardiovascular Society; CHF, congestive heart failure; CI, 
confidence interval; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; 
eGFR, estimated glomerular filtration rate; HR, hazard ratio; LVEF, left ventricular ejection 
fraction; MI, myocardial infarction; NYHA, New York Heart Association; PAD, peripheral artery 
disease; SBP, systolic blood pressure. 
 
